The results showed that high MAD2L1 expression in HCC was closely associated with PD1, PD-L1, CTLA-4, and TIGIT expression, suggesting that targeting MAD2L1 may improve the efficacy of immunotherapy in HCC. Here, MAD2L1 is linked to hepatocellular carcinoma.